United Therapeutics (UTHR) Misses Q2 EPS by 63c
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $492.02 --0%
EPS Growth %: -10.1%
Financial Fact:
Diluted (in shares): 46.2M
Today's EPS Names:
VIVO, PMCB, PLCE, More
EPS Growth %: -10.1%
Financial Fact:
Diluted (in shares): 46.2M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $5.85, $0.63 worse than the analyst estimate of $6.48. Revenue for the quarter came in at $714.9 million versus the consensus estimate of $689.93 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toro Company (TTC) Tops Q3 EPS by 3c; offers guidance
- AIAI Holdings signs LOI to acquire defense firm from affiliated entity
- BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
